A carregar...
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellul...
Na minha lista:
| Publicado no: | Clin Mol Hepatol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Korean Association for the Study of the Liver
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5760005/ https://ncbi.nlm.nih.gov/pubmed/29151326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2017.0108 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|